Shots:

• The first patient has been dosed in the P-II AAVIATE trial to assess the suprachoroidal delivery of RGX-314 (2.5x1011 GC/eye & 5x1011 GC/eye) vs ranibizumab (0.5mg- monthly- IVT) using the SCS Microinjector in ~40 patients in a ratio (3:1) with wet AMD
• The 1EPs of the study is mean change in vision in patients dosed with RGX-314- as measured by BCVA @40wks.- other endpoints include mean change in CRT and number of anti-VEGF IVT received following administration of RGX-314
• The company expects to report interim data of the first cohort of the trial by the end of 2020. RGX-314 is consists of the NAV AAV8 vector- being developed as a potential one-time treatment for wet AMD- diabetic retinopathy- and other chronic retinal conditions and has shown a positive effect in patients with wet AMD when delivered subretinally in the ongoing P-I/IIa study

­ Ref: Regenxbio | Image: Regenxbio